Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in vitro studies.

[1]  K. Yasuda,et al.  Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase. , 2021, Drug metabolism and pharmacokinetics.

[2]  Peijin Zhang,et al.  Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator , 2021, Drug Metabolism and Disposition.

[3]  H. Yamazaki,et al.  In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  Koji Matsumoto,et al.  DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[5]  T. Taguchi,et al.  Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males , 2018, Clinical Drug Investigation.

[6]  T. Taguchi,et al.  Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study , 2017, BMJ Open Diabetes Research & Care.

[7]  P. Chavatte,et al.  Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors. , 2017, Journal of medicinal chemistry.

[8]  T. Fukami,et al.  Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity. , 2016, Biochemical pharmacology.

[9]  A. Cavalli,et al.  Anandamide hydrolysis in FAAH reveals a dual strategy for efficient enzyme-assisted amide bond cleavage via nitrogen inversion. , 2015, The journal of physical chemistry. B.

[10]  T. Fukami,et al.  Screening of Specific Inhibitors for Human Carboxylesterases or Arylacetamide Deacetylase , 2014, Drug Metabolism and Disposition.

[11]  Diansong Zhou,et al.  Metabolism of a G Protein-Coupled Receptor Modulator, Including Two Major 1,2,4-Oxadiazole Ring-Opened Metabolites and a Rearranged Cysteine-Piperazine Adduct , 2012, Drug Metabolism and Disposition.

[12]  William M Hardesty,et al.  Metabolism of [14C]GSK977779 in Rats and Its Implication with the Observed Covalent Binding , 2011, Drug Metabolism and Disposition.

[13]  P. Lam,et al.  Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs , 2008, Drug Metabolism and Disposition.

[14]  T. Mikkelsen,et al.  A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals* , 2006, Journal of Biological Chemistry.

[15]  H. Perrier,et al.  Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560. , 2006, Journal of mass spectrometry : JMS.

[16]  Daniele Piomelli,et al.  Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.

[17]  S. Kitamura,et al.  The Role of Mammalian Intestinal Bacteria in the Reductive Metabolism of Zonisamide , 1997, The Journal of pharmacy and pharmacology.

[18]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[19]  S. Kitamura,et al.  Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[20]  G. Mannens,et al.  The metabolism and excretion of risperidone after oral administration in rats and dogs. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[21]  M. Howard,et al.  The use of liquid chromatography/thermospray mass spectrometry with on-line ultraviolet diode array and radiochemical detection: characterization of the putative metabolites of U-78875 in female rat faeces. , 1994, Biological mass spectrometry.

[22]  G. Mannens,et al.  Absorption, metabolism, and excretion of risperidone in humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[23]  S. Ohmori,et al.  Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[24]  S. Ohmori,et al.  Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. , 1993, Molecular pharmacology.

[25]  Ze-Qiang Ma,et al.  Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative , 1992 .

[26]  R R Scheline,et al.  Metabolism of foreign compounds by gastrointestinal microorganisms. , 1973, Pharmacological reviews.

[27]  S. Lan,et al.  Metabolic studies with trans-5-amino-3-(2-(5-nitro-2-furyl)vinyl)-1,2,4-(5- 14 C)oxadiazole (SQ 18,506). 1. Reductive cleavage of the 1,2,4-oxadiazole ring. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.